BioSpace News Archive

ACELYRIN, INC. announced that ACELYRIN’s founder Shao-Lee Lin, M.D., Ph.D. has stepped down as Chief Executive Officer and that Mina Kim, chief legal and administrative officer at ACELYRIN, has been appointed Chief Executive Officer and to the company’s Board of Directors.

AEON Biopharma, Inc. provided an update on the status of its late-stage clinical pipeline for ABP-450 that targets multiple indications.

NEXGEL, Inc. today announced it will report its financial results for the first quarter 2024, after the market closes on May 13, 2024.

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Movano Health (Nasdaq: MOVE) announced that it successfully submitted updated pivotal clinical trial results as well as proof of enhanced medical device usability on April 22, 2024 to the U.S. Food and Drug Administration (FDA) as part of its 510(k) filing for the Company’s first commercial medical device, the Evie Med Ring pulse oximeter.

Rallybio Corporation today reported first quarter financial results for the period ended March 31, 2024 and provided an update on recent company developments.

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2024 and recent business highlights.

Bausch Health Companies Inc. today announced award-winning actor, Bellamy Young, as the brand ambassador in a new campaign to raise awareness of Xifaxan, the first and only FDA approved medication to reduce the risk of overt hepatic encephalopathy (OHE) recurrence in adults.

Sangamo Therapeutics, Inc. today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.

Nexalin Technology, Inc. is pleased to invite investors to a webinar on May 23, 2024, at 4:15 p.m. ET.